Skip to main content
Equibles
IMMX logo

IMMX · Immix Biopharma, Inc.

Track IMMX — free

Use IMMX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IMMX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$13.16 -0.03 (-0.23%) At close · Aug 20
Going-concern doubt — flagged Aug 7, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. The continuation of the Company as a going concern is dependent upon its ability to obtain continued financial support from its stockholders, necessary equity financing to continue operations and the attainment of profitable operations.”
View the 10-Q filed Aug 7, 2026
Market Cap
$943.60M
Shares
71.54M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.16 Open$12.98 Day$12.69–13.20 52W close$1.96–13.19 Avg vol 30d1.6M Short int9.5M · 13.3% float · 5.2d Short vol53% DataDec 2021–Aug 2026 Filing10-Q · Aug 7

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 7, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +66%
above
Price vs 50-day avg +33%
above
RSI (14) 72
overbought
MACD trend Positive
52-week position 100%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +50%
trailing
6-month return +63%
trailing
YTD return +152%
this year
Relative strength +52%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +44 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
13.27% of float · ▲ +11.7% MoM · 5.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
108 holders — near 3-yr high, broad support
Squeeze score 76
high risk · 0–100
Fundamentals
Weak
EPS growth −17%
Y/Y
Free cash flow $-24.7M
Balance sheet $93.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 87%
annualized · 1-yr
Max drawdown −40%
past year
ATR 6.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+66% Bullish
Price vs 50-day avg
+33% Bullish
RSI (14)
72 Bearish
MACD trend
Positive Bullish
52-week position
100% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +44 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
13.27% of float · ▲ +11.7% MoM · 5.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
108 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $13 · 100% Range high $13
vs 200-day avg +66% vs 50-day avg +33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IMMX
Immix Biopharma, Inc.
this stock
$943.60M +151.6% — — 13.3%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
108
% held
78.8%
Net QoQ
+29.1M sh
Top holder
Jupiter Topco LLC
Held Float
View
Held by Funds
Fund positions
29
View
Short & Settlement
Short Interest Rising
Shares short
9.5M
Days to cover
5.2d
Change
+991.5K sh
View
Short Volume
Short vol %
53%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
38.3K
Value
$360.7K
As of
Jul 23, 2026
View
Off-Exchange
Off-exchange %
44.3%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-29.4M
EPS diluted
$-0.89
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 7, 2026
This year
11
View
Exempt Offerings
Offering
Indefinite
Filed
May 20, 2024
View

Performance

5D 20D 120D MTD YTD
IMMX +20.5% +49.6% +63.1% +58.2% +151.6%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY +22.5% +46.2% +51.9% +56.1% +139.8%
Key facts CIK 1873835 CUSIP 45258H106 13F (30d) 108 filings 107 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)